Search | Clinical Trials Finder

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Sertraline, Venlafaxine-XR; Drug
Lead sponsor: BRC Operations Pty. Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 2,688 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2019
U.S. locations: 13
States / cities: Colton, California • Mission Viejo, California • Stanford, California + 9 more

Conditions: Depression
Interventions: venlafaxine XR plus aripiprazole, venlafaxine plus placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 60 Years and older
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: St Louis, Missouri • Pittsburgh, Pennsylvania

Conditions: Healthy
Interventions: LDX + Venlafaxine XR, Venlafaxine XR + LDX; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Treatment-resistant Depression
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 10
States / cities: Birmingham, Alabama • Orange, California • San Rafael, California + 7 more

Conditions: Roux en Y Gastric Bypass, Sleeve Gastrectomy
Interventions: Venlafaxine IR and Venlafaxine XR; Drug
Lead sponsor: North Dakota State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Treatment-resistant Depression
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 37
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more

Conditions: Depression
Interventions: Venlafaxine XR, Placebo, JNJ26489112; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 14
States / cities: Arcadia, California • Escondido, California • San Diego, California + 11 more

Conditions: Depression
Interventions: Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro), Placebo, Interpersonal Clinical Interaction (ICI); Drug · Other · Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder, Breast Cancer, Venlafaxine
Interventions: Interpersonal Psychotherapy, Venlafaxine HCl ER; Behavioral · Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 53
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more

Conditions: Alcohol-Related Disorders, Anxiety Disorders
Interventions: Venlafaxine, CBT, Progressive muscle relaxation therapy (PMR), Placebo medication; Drug · Behavioral · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Placebo, Brexpiprazole, ADT; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more

Conditions: Major Depressive Disorder
Interventions: Brexpiprazole, Antidepressant therapy; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder
Interventions: SSRI + placebo, Escitalopram + Bupropion SR, Venlafaxine XR + Mirtazapine; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 15
States / cities: Tuscaloosa, Alabama • Harbor City, California • Los Angeles, California + 12 more

Conditions: Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Interventions: Gabapentin, Methadone, Oxycodone, Quality-of-Life Assessment, Questionnaire Administration, Venlafaxine, Venlafaxine Hydrochloride Extended Release; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Major Depressive Disorder
Interventions: sertraline, venlafaxine XR; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Generalized Anxiety Disorder
Interventions: Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day, Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 36
States / cities: Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more

Conditions: Major Depression Disorder
Interventions: Adjunct brexpiprazole, ADT; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 65 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 13
States / cities: Arcadia, California • Miami, Florida • Orlando, Florida + 9 more

Conditions: Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions: Bupropion Hydrochloride Extended-release, Extended-release Venlafaxine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 45
States / cities: Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 40 more

Conditions: Bipolar Disorder
Interventions: Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: Not listed
Enrollment: 1,037,352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Obsessive-Compulsive Disorder
Interventions: Serotonin reuptake inhibitors management, Cognitive behavioral therapy by a psychologist, Instructional cognitive behavioral therapy by a psychiatrist; Drug · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 7 Years to 17 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 3
States / cities: Durham, North Carolina • Philadelphia, Pennsylvania • Providence, Rhode Island

Conditions: Bariatric Surgery, Gastric Bypass, Roux-en-Y Gastric Bypass
Interventions: venlafaxine ER (extended-release) 75 mg; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Major Depressive Disorder, Healthy Controls
Interventions: Any FDA Approved Antidepressant; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Major Depressive Disorder, Depression
Interventions: venlafaxine XR, buprenorphine, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 50 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

International Study to Predict Optimised Treatment - in Depression

Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)

Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Venlafaxine PK Following Bariatric Surgery

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder

Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression

Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

Psychosocial and Medication Treatment for Anxiety in Alcoholism

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

Combining Medications to Enhance Depression Outcomes

Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy

Sertraline vs. Venlafaxine XR

A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone

Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment

Sexual Functioning Study With Antidepressants

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Treatment of Obsessive Compulsive Disorder in Children

Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels

Effects of Treatment on Decision-making in Major Depression

Buprenorphine Used With Treatment Resistant Depression in Older Adults